Search
Gyre Therapeutics Inc
GYREAdd to Watchlist
6.550USD
-0.450-6.43%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
598.49MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-6.43%
5 Days
-12.32%
1 Month
-17.09%
6 Months
-18.02%
Year to Date
-7.22%
1 Year
-42.29%
TradingKey Stock Score of Gyre Therapeutics Inc
Currency: USD Updated: 2026-05-15Key Insights
Gyre Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 93 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.67.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Gyre Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Gyre Therapeutics Inc Highlights
StrengthsRisks
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
Undervalued
The company’s latest PE is -93.41, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.60M shares, increasing 21.44% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 2.63K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.39.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
18.667
Target Price
+166.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Gyre Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Gyre Therapeutics Inc Info
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
Ticker SymbolGYRE
CompanyGyre Therapeutics Inc
CEOZhang (Ping)
Websitehttps://www.gyretx.com/
Related Instruments
-0.03%
-1.75%
-0.15%
-1.11%
-1.77%
-1.79%
-2.22%
-1.88%
-2.35%
-1.63%
+0.43%
-2.99%
-0.37%
-1.64%
+1.79%
0.00%
-2.05%
-0.15%
-2.77%
+0.41%Popular Instruments
102.160
+3.297 (+3.33%)
300.230
+2.020 (+0.68%)
225.320
-10.420 (-4.42%)
4538.710
-111.520 (-2.40%)
482.020
-7.101 (-1.45%)
1407.610
+24.890 (+1.80%)
724.660
-51.350 (-6.62%)
396.780
-4.290 (-1.07%)
78065.220
-165.780 (-0.21%)
422.240
-21.060 (-4.75%)
